ClinicalTrials.gg
RecruitingNCT07054359HIPOCAMPUpdated Oct 8, 2026

"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"

An interventional study of HBsAg RDT Women and Treatment by TDF if HBcrAg RDT positive in HBV Infection and Pregnancy, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 1 site in Vietnam. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by ANRS, Emerging Infectious Diseases · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 8, 2026Now RecruitingFirst site in Vietnam+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,200
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral prophylaxis (PAP) by tenofovir. Current international guidelines require hepatitis B surface antigen (HBsAg)-positive pregnant women to undergo viral load (VL) quantification to identify those at high risk (VL ≥200,000 IU/mL) who should receive PAP. However, VL testing remains inaccessible in many low- and middle-income countries (LMICs), particularly in rural areas. Consequently, in the forthcoming guidelines, the WHO is going to issue a conditional recommendation for administering PAP to all HBsAg-positive women lacking access to VL testing. Although this universal strategy may appear promising for simplifying the diagnostic process, it may result in overtreating the majority of HBsAg-positive pregnant women, estimated at 85% in Africa and 70% in Asia, for whom birth dose vaccine is likely sufficient. Moreover, the real-world applicability of this strategy in LMICs has never been formally tested.

As an innovative alternative, the adoption of a rapid point-of-care test for hepatitis B core-related antigen (HBcrAg-RDT) is proposed to identify women eligible for PAP.This test requires only a drop of capillary blood, eliminating the need for electricity or centrifugation, and can provide a reliable result within 45 minutes. Compared to the universal strategy, HBcrAg-RDT strategy is expected to be less expensive and could prevent unnecessary tenofovir exposure for both women and their fetuses. Our aim is to establish the non-inferiority of the HBcrAg-RDT strategy, in comparison to the universal strategy, in terms of effectiveness, defined as the reduction in maternal VL at the time of childbirth, a main driver of the MTCT risk. This will be approached through a multidisciplinary framework integrating health economics, implementation science, and health policy analysis.

Read the detailed description

I) Methodology and Study Design

The study combines two components:

I. Core Research Study Study Design Two-Arm Parallel, Cluster-Randomized Trial Design, Open-Label, Non-Inferiority Trial 1:1 Allocation Ratio 1:1 Arm 1: Intervention Group (Selective Strategy) HBsAg-positive women → Tested for HBcrAg RDT → TDF treatment if HBcrAg positive.

Arm 2: Control Group (Universal Strategy) HBsAg-positive women → Immediate TDF treatment

Clusters Randomization unit: Primary Health Centers (PHCs) or rural hospitals Total clusters: 80 (40 per group, 16 clusters per country)

Participants Total participants: 3200 HBsAg-positive women 1600 women per group → 640 women per country → 40 per cluster

Key eligibility criteria for clusters include:

  • Rural or semi-rural location.
  • No involvement in similar strategies
  • No routine HBV DNA or HBeAg testing.
  • Enough antenatal care visits to reach the target of 40 HBsAg-positive women in one year
  • At least two nurses or midwives.
  • HBV vaccination program in place
  • Motivation to participate.

II. The Social Science component:

The social sciences component of the study will be conducted in only 2 countries (Cambodia and Ivory Coast) and includes three key sub-studies:

  • The socio-economic and behavioral study aims to assess i) the acceptability of the two strategies by the healthcare workers involved in implementing the trial in the study sites and by the pregnant women who will participate in the trial and benefit from HBV PMTCT interventions, ii) the impacts of the strategies on health literacy, HBV knowledge, perceived health, treatment adherence and retention into care, iii) women experience related to HBV status disclosure and perceptions on HBV partner and children screening
  • The health economic evaluation will analyze the strategies' costs, benefits, and cost-effectiveness, considering health and cost outcomes over the study period and the long term.
  • The health policy study will evaluate the feasibility and sustainability of the strategies at the institutional level and explore political, institutional, and social factors that influence integrating the study results into national health policies.

A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers.

Additionally, a qualitative assessment of the two strategies' acceptability, alongside a health policy analysis, will be conducted in Togo to enrich the study's contextual understanding. This initiative will also enhance the partner team's social science research capacity through targeted training and skill development in qualitative research for students and early-career researchers.

II) Intervention:

Medication: Tenofovir Disoproxil Fumarate (TDF); Administration Route: Oral Dosage: 300 mg/day or 300 mg every 2 days (if creatinine clearance is 30-50 ml/min)

Preventive treatment:

  • Initiated during inclusion visit (if eligible for treatment in group 1, and for all in group 2)
  • Continued until the 6-8 weeks postpartum visit Post-partum assessment and treatment At 3-month postpartum, all HBsAg-positive women will undergo a liver disease assessment at the closest district or provincial hospital. This assessment will include HBV DNA, HBeAg, HBcrAg-RDT, ALT/AST, platelet count, and liver ultrasound. Criteria for resuming treatment will follow the 2024 WHO guidelines. In case of TDF resumption, the treatment will be funded by the trial for 6 months, and the woman will be followed at a district or provincial hospital

III) Statistical methods

Core research study. The investigators predict that with the universal strategy, the proportion of women meeting the primary endpoint would be 78%. They chose a non-inferiority margin of 10% when comparing the HBcrAg-RDT strategy to the universal strategy. This indicates that a 68% success rate would be accepted for the same primary endpoint under the worst-case HBcrAg-RDT strategy.

They plan to recruit 40 HBsAg-positive women in each PHC. With a coefficient of variation between clusters of 0.143, derived from the assumptions, the trial requires 40 clusters per group, totaling 80 clusters of 40 HBsAg-positive women each, for 90% power at two-sided 5% (2.5% one-sided) significance to show non-inferiority within a margin of 10%.

Social Science quantitative data:

The sample size for the social science data is based on the proportion of women with good knowledge of hepatitis B, 90% power, two-sided 5% significance, and 20% loss to follow-up at the 9-month postpartum visit. Assuming 23% and 29% of women having good knowledge of hepatitis B at inclusion and the 9-month postpartum visit, respectively, overall for both strategies, with a correlation coefficient before-after of 0.15, 32 clusters (16 per country) of 40 women each (totaling 1280 participants) will be needed to show significant differences in the proportion of women with good knowledge of hepatitis B between inclusion and the 9-month postpartum visit (overall, considering both strategies together).

02

Conditions studied

  • HBV Infection
  • Pregnancy

Browse trials for

Keywords

  • Pregnancy
  • Mother to child transmission
  • Public health
  • Hepatitis B
  • Cluster-randomized controlled trial
03

In context

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.

This study's planned enrollment of 3,200 is above the median of 145 across 758 interventional studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old, or ≥ the legal age of majority as defined by each country, on the day of inclusion.
  2. Pregnancy.
  3. Intention to attend antenatal care visits in the Primary Health Center or the Rural Hospital
  4. Living in an area covered by the Primary Health Center or the Rural Hospital on the start date of the trial
  5. Positive identified during the screening phase of the study
  6. Free, informed, and written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out as part of the study.

Exclusion criteria

Exclusion Criteria:

  1. co-infection.
  2. treatment ongoing on the day of inclusion.
  3. Having at least one of the following criteria indicatives of the third trimester of pregnancy:

    • Gestational Age-Based Exclusion:

    The reported gestational age is ≥28 weeks, based on the last menstrual period (LMP) if known.

    • Ultrasound-Based Exclusion:

    Fetal biometry (e.g., head circumference, femur length) on ultrasound suggests a gestational age of ≥28 weeks.

    • Fundal Height-Based Exclusion:

    Symphysis-fundal height (SFH) measurement of ≥ 28 cm which corresponds to approximately 28 weeks of gestation.

  4. Severe gravid disease at inclusion, which poses a life-threatening risk to the mother and/or child
  5. Any concomitant medical condition that, according to the clinical site investigator, would contraindicate participation in the study.
  6. Concurrent participation in any other study (unless approved in writing by the Global Principal Investigators).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,200 participants (estimated)

Study arms

  • Other
    Universal strategy

    Pregnant women who test positive for HBsAg will initiate TDF preventive treatment on the same day of their visit. Their child/children will be enrolled in the study until 9 months.

    Diagnostic Test: HBsAg RDT Women · Drug: Treatment by TDF · Other: Social sciences component · Diagnostic Test: HBsAg RDT Infants

  • Experimental
    Selective strategy

    Pregnant women who test positive for HBsAg will be tested for HBcrAg RDT on the same day of their visit, and those who test positive will initiate TDF preventive treatment on the same date.Their child/children will be enrolled in the study until 9 months.

    Diagnostic Test: HBsAg RDT Women · Drug: Treatment by TDF if HBcrAg RDT positive · Other: Social sciences component · Diagnostic Test: HBsAg RDT Infants

Interventions

  • Diagnostic testHBsAg RDT Women

    HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test

  • DrugTreatment by TDF if HBcrAg RDT positive

    300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)

  • DrugTreatment by TDF

    300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)

  • OtherSocial sciences component

    The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study. A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers

  • Diagnostic testHBsAg RDT Infants

    At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.

06

What researchers measure

Primary outcomes

  1. Percentage of HBsAg-positive women with HBV DNA <200,000 IU/mL at the time of delivery

    The primary endpoint will be the percentage of HBsAg-positive women who present at healthcare facilities for delivery and have an HBV DNA \<200,000 IU/mL at the time of delivery.

    Time frame: Delivery

Secondary outcomes

  1. Percentage of infants positive for HBsAg

    Time frame: At 9 months of life

Other outcomes

  1. Percentage of women eligible for PAP who started TDF

    Time frame: At screening

  2. Percentage of women eligible for PAP who completed TDF prophylaxis

    Time frame: up to 40 weeks of gestation

  3. Percentage of women with adherence >90% at each study visit based on pill counts and self-report

    Time frame: from inclusion to delivery, max 40 weeks

  4. Percentage of infants receiving HepB-BD

    Time frame: up to 9 months

  5. Percentage of infants with a complete HepB vaccination schedule

    Time frame: up to 9 months

  6. Percentage of women or infants with a serious adverse event (SAE) leading to death, or leading to treatment discontinuation up to delivery and Adverse Events of Special Interest

    Time frame: through study completion, an average of 27 months

  7. Percentage of women who underwent liver disease assessment and factors associated with retention in care.

    Time frame: At 3 months postpartum

  8. Percentage of women eligible for long-term TDF treatment

    Time frame: At 3 months post-partum

  9. Accuracy (sensitivity, specificity, positive and negative predictive values) of the simplified score (HBcrAg-RDT & ALT) to predict eligibility for the long-term TDF treatment

    Time frame: At inclusion and 3 months after delivery

  10. Communicative Health Literacy (COM_HL) on hepatitis B and related risks, empowerment, and health literacy among women and healthcare workers and factors associated

    Minimum total score = 5 Maximum total score = 25 Low score: Indicates low communicative literacy. High score : Reflects a good ability to interact effectively in a healthcare context

    Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery

  11. Measures of the disclosure of HBV status among women and experience of sharing HBV status anf factors associated.

    Percentage of women who disclosed their HBV status to their partner and HBV disclosure score/moral support and discrimination scales

    Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery

  12. Percentage of partners and children who have been screened for HBV

    Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery

  13. Measures of perceived health and quality of life among women, the internalized stigma of mental illness and factors associated.

    Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery

  14. Acceptability for each strategy among healthcare workers, assessed using a scale adapted from Sekhon et al., 2022 to the intervention.

    Minimal total score= 0 Maximal total score= 100 Low score indicates low acceptability High score indicates high acceptability

    Time frame: Before HCW training and at the end of the study (18-24 month after the study starts)

  15. . Measures of preferences of healthcare providers between the two strategies and associated factors

    Declared preferences of HCW between theoretical scenarios exhibiting various characteristics (time to get a diagnostic in minutes, cost for women in dollars, specificity and sensibility of the test in percentage)

    Time frame: Before HCW training and at the end of the study (18-24 month after the study starts)

  16. .Cost per pregnant woman of the universal and of the targeted strategy, from the moment they are screened positive with the HBAgS (RDT)

    Costs will be estimated based on a societal approach, including all expenses for the healthcare system and the costs (direct and indirect) for the women and their households, and will be estimated using a dedicated data collection tool administrated during the duration of the project, relying on a micro-costing approach (see section 3.2.2 of the protocol, Health Economic Evaluation).

    Time frame: until 9 months after delivery

  17. Incremental cost-effectiveness ratio (ICER)

    ICER wil be calculated as the difference in costs between the two strategies (incremental cost) divided by the difference in health benefits (infections avoided and mortality avoided between the two strategies). The ICER will be expressed as an additional cost (in dollars) per infection avoided. Lower ICER indicates greater cost-effectiveness of the assessed strategy.

    Time frame: At the end of follow_up after 27 months

07

Study locations

1 of 1 sites recruiting
  • Tien lang District Health center
    Haiphong, Vietnam
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2028, 27 months after the start.

Of 62 non-industry interventional studies with no phase under Hepatitis B, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 27 months is close to that.

Counting every sponsor, half of 68 studies reached it within 29 months; a quarter within 11 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Nov 2025 → Aug 2026, primary completion Nov 2026 → Nov 2028 and completion Jan 2028 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jul 8, 2025
StartActual
Aug 10, 2026was Nov 2025
Primary completionEst.
Nov 10, 2028was Nov 2026
CompletionEst.
Nov 10, 2029was Jan 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added — first site in Vietnam
Show site
  • Tien lang District Health center · Haiphong, Vietnam
Oct 8, 2026
Start date
Nov 2025→Aug 10, 2026 (actual)
Oct 8, 2026
Primary completion
Nov 2026→Nov 10, 2028
Oct 8, 2026
Study completion
Jan 2028→Nov 10, 2029
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Vietnam
    Show site
    • Tien lang District Health center · Haiphong, Vietnam
    Start date Nov 2025→Aug 10, 2026 (now actual)
    Primary completion Nov 2026→Nov 10, 2028
    Study completion Jan 2028→Nov 10, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07054359
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Aug 10, 2026
Primary completion
Nov 10, 2028 (estimated)
Completion
Nov 10, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Olivier SEGERAL
Contact
olivier.segeral@hug.ch
+ 41 79 553 6535
Yusuke SHIMAKAWA
Contact
yusuke.shimakawa@pasteur.fr
+33 (0)1 40 61 39 58
Olivier SEGERAL
study director · University Hospital, Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion